ACRS vs BDX · rev $3.6M vs P/E 34, rev $21.84B
Aclaris Therapeutics Inc (ACRS) versus Becton Dickinson and Company (BDX) — a side-by-side from cached financials, not a winner call.
Aclaris Therapeutics Inc (ACRS) is a biotechnology company listed on NASDAQ.
Becton Dickinson and Company (BDX) is a medical instruments & supplies company listed on US.
Latest reported ACRS revenue for 2026-06-30 was $3.6M. Net income was -$41.3M. Revenue was up 81.6% from 2026-03-31 to 2026-06-30. ACRS currently screens at market cap $615.9M.
Latest reported BDX revenue for 2025-09-30 was $21.84B. Net income was $1.68B. BDX currently screens at market cap $50.30B and trailing P/E 33.9.
ACRS currently screens at market cap $615.9M. BDX currently screens at market cap $50.30B and trailing P/E 33.9.
Not investment advice. Open the ACRS and BDX stock pages for the full models.
Not investment advice.